MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
Climacteric. 2022 Feb;25(1):88-95. doi: 10.1080/13697137.2021.1951204. Epub 2021 Jul 26.
The musculoskeletal conditions osteoporosis and sarcopenia are highly prevalent in older adults. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone, whereas sarcopenia is identified by the loss of muscle strength, function and mass. Osteoporosis represents a major health problem contributing to millions of fractures worldwide on an annual basis, whereas sarcopenia is associated with a range of adverse physical and metabolic outcomes. They both affect physical and social function, confidence and quality of life as well as contributing to high health-care costs worldwide. Osteosarcopenia is the term given when both conditions occur concomitantly and it has been suggested that interactions between these two conditions may accelerate individual disease progression as co-existence of osteoporosis and sarcopenia is associated with higher morbidity from falls, fracture, disability as well as mortality. In this review, we will outline the epidemiology, pathogenesis and clinical consequences of osteosarcopenia and discuss available management strategies.
肌肉骨骼疾病骨质疏松症和肌肉减少症在老年人中非常普遍。骨质疏松症的特征是骨量低和骨微观结构恶化,而肌肉减少症则表现为肌肉力量、功能和质量的丧失。骨质疏松症是一个主要的健康问题,每年在全球导致数百万人骨折,而肌肉减少症则与一系列不良的身体和代谢后果有关。它们都影响身体和社会功能、信心和生活质量,并导致全球医疗保健费用增加。当这两种情况同时发生时,就会出现“骨肌减少症”这一术语,有人认为这两种情况之间的相互作用可能会加速个体疾病的进展,因为骨质疏松症和肌肉减少症并存与更高的跌倒发病率、骨折、残疾和死亡率有关。在这篇综述中,我们将概述骨肌减少症的流行病学、发病机制和临床后果,并讨论现有的管理策略。